EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial

Maryam Mosaffa-Jahromi, Hossein Molavi Vardanjani, Andrea Fuzimoto, Jennifer Hunter, Kamran Bagheri Lankarani, Mehdi Pasalar

Frontiers in Pharmacology · 16.01.2024 · 15

DOI: 10.3389/fphar.2024.1331177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.01.2024. Verfasst von Maryam Mosaffa-Jahromi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastrointestinal symptoms are prevalent amongst patients with a confirmed diagnosis of COVID-19 and may be associated with an increased risk of disease severity. This trial aimed to evaluate the efficacy and safety of aniseed ( Pimpinella anisum L.) powder as an add-on therapy to standard care for treating gastrointestinal symptoms experienced by adults with an acute SARS-CoV-2 infection.

Methods

The study was a randomized parallel-group double-blinded placebo-controlled add-on therapy trial. Adults with an acute SARS-CoV-2 infection who did not require hospitalization and reported at least one gastrointestinal symptom in the preceding 48 h were assigned to either the aniseed or placebo group in a 1:4 ratio. All 225 participants (45 in the aniseed group and 180 in the placebo group) were instructed to use 25 g of powdered aniseed or placebo twice daily for 2 weeks. The primary outcomes were the proportion of patients who experienced an improvement of at least one point in the symptom score after adjusting for age group, gender, and time. Backwards stepwise logistic regression was applied to calculate the risk ratios. The clinical symptoms and adverse events were assessed at the beginning, 1 week later, and at the end of the trial (week two).

Results

Participants in the aniseed group were significantly more likely to report symptom improvement for abdominal pain [adjusted risk ratio (RR):0.55; 95% confidence interval (CI): 0.46–0.72], anorexia (RR:0.62; 95% CI: 0.47–0.82), and diarrhea (RR:0.19; 95% CI: 0.12–0.30), but not nausea/vomiting (RR:0.87; 95% CI: 0.71–1.08) or bloating (RR:0.87; 95% CI: 0.72–1.05). Two participants in the aniseed group and three participants in the placebo group reported mild to moderate adverse events.

Conclusion

This study showed that 2 weeks of aniseed powder containing trans-anethole (87%–94%) may help improve abdominal pain, anorexia, and diarrhea in COVID-19 patients. The findings align with the known biological, multitargeted activity of P. anisum and trans-anethole, which includes inhibiting SARS-CoV-2 along with other anti-infective, anti-inflammatory, antioxidant, hepatoprotective, and anti-dysbiosis properties. Multicenter trials with larger sample sizes and longer follow-up are warranted to confirm these findings. Clinical Trial Registration: Iranian Registry of Clinical Trials (IRCT20120506009651N3).

Schlagwörter

Stichwörter der Autor:innen

COVID-19Persian medicineabdominal painaniseeddiarrheagastrointestinal symptom

Autor:innen und Institutionen

  • Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Holistic Sync, Holistic Integrative Medicine, Rio, Brazil.
  • Health Research Group, Sydney, NSW, Australia.
  • Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Zitieren

APA

Mosaffa-Jahromi, M., Molavi Vardanjani, H., Fuzimoto, A., Hunter, J., Lankarani, K. B., & Pasalar, M. (2024). Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1331177

Vancouver

Mosaffa-Jahromi M, Molavi Vardanjani H, Fuzimoto A, Hunter J, Lankarani KB, Pasalar M. Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1331177

BibTeX
@article{MosaffaJahromi2024,
  author = {Mosaffa-Jahromi, Maryam and Molavi Vardanjani, Hossein and Fuzimoto, Andrea and Hunter, Jennifer and Lankarani, Kamran Bagheri and Pasalar, Mehdi},
  title = {Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1331177}
}
Kostenlos starten →